PN LOGO.jpg
Precision Neuroscience Raises $102 Million to Advance AI-Powered Brain Implant
16 déc. 2024 07h00 HE | Precision Neuroscience
The raise brings Precision’s total funding to $155 million, solidifying its position as a leader in the brain–computer interface industry.Investors include General Equity Holdings, B Capital, Stanley...
arvinas_logoART_lg.jpg
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
10 déc. 2024 09h05 HE | Arvinas Inc.
– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society
06 déc. 2024 12h00 HE | Neurona Therapeutics
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meet
arvinas_logoART_lg.jpg
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
27 nov. 2024 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
25 nov. 2024 17h35 HE | Arvinas Inc.
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San...
Firefly.png
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
14 nov. 2024 17h30 HE | Firefly Neuroscience, Inc.
Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company’s...
sns insider pvt ltd.png
Neuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S Insider
11 nov. 2024 11h45 HE | SNS Insider pvt ltd
Austin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- “According to S&S Insider, The Neuroscience Market Size was valued at USD 35.3 billion in 2023 and is projected to reach to USD 50.2 billion by 2032,...
Firefly.png
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
06 nov. 2024 09h00 HE | Firefly Neuroscience, Inc.
TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
04 nov. 2024 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
30 oct. 2024 07h00 HE | Arvinas Inc.
– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be...